Grufity logoGrufity logo

DexCom Inc Stock Research

DXCM

114.56USD+0.84(+0.74%)Market Closed

Market Summary

USD114.56+0.84
Market Closed
0.74%

DXCM Alerts

DXCM Stock Price

DXCM RSI Chart

DXCM Valuation

Market Cap

44.3B

Price/Earnings (Trailing)

129.7

Price/Sales (Trailing)

15.21

EV/EBITDA

77.15

Price/Free Cashflow

145.24

DXCM Price/Sales (Trailing)

DXCM Profitability

EBT Margin

13.43%

Return on Equity

16.01%

Return on Assets

6.33%

Free Cashflow Yield

0.69%

DXCM Fundamentals

DXCM Revenue

Revenue (TTM)

2.9B

Revenue Y/Y

16.76%

Revenue Q/Q

5.93%

DXCM Earnings

Earnings (TTM)

341.2M

Earnings Y/Y

1.8K%

Earnings Q/Q

-9.29%

Price Action

52 Week Range

66.89134.76
(Low)(High)

Last 7 days

0.9%

Last 30 days

-3.9%

Last 90 days

-2.2%

Trailing 12 Months

9.3%

DXCM Financial Health

Current Ratio

1.99

DXCM Investor Care

Buy Backs (1Y)

0.44%

Diluted EPS (TTM)

0.82

Peers (Alternatives to DexCom)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
104.1B
18.4B
2.26% 8.00%
44.16
5.64
7.84% 18.25%
84.2B
6.2B
-4.47% -13.27%
63.66
13.53
8.97% -22.43%
69.1B
12.7B
0.59% 12.45%
99.06
5.45
6.68% -32.95%
67.4B
19.0B
-5.16% -6.78%
41.86
3.55
-0.43% -8.78%
49.8B
5.4B
2.41% -25.12%
32.74
9.26
2.86% 1.25%
MID-CAP
7.2T
489.7M
9.34% 31.15%
82.2K
16.8K
106.51% 2464.23%
10.2B
847.1M
-3.64% 34.52%
-5.1K
12.05
13.32% -137.89%
5.2B
1.0B
-11.64% -20.31%
30.19
5.09
6.76% 24.45%
3.5B
410.9M
4.51% -3.13%
-29.82
8.43
27.29% -14.60%
2.7B
801.2M
1.13% -58.87%
-28.25
3.34
14.00% -707.69%
SMALL-CAP
1.7B
138.6M
-15.68% 29.18%
-30.43
12.07
36.62% -10.44%
1.6B
350.9M
10.38% 49.06%
-10.84
4.7
44.26% -5.42%
1.3B
820.0M
-8.35% -12.22%
25.89
1.59
10.13% 701.59%
828.4M
239.8M
0.30% 1.49%
-21.88
3.45
-4.74% -31.15%

Financials for DexCom

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue4.2%2,9102,7932,6732,5722,449
Gross Profit3.8%1,8831,8141,7671,7351,681
Operating Expenses-3.6%1,4921,5481,5301,4741,415
  S&GA Expenses6.6%1,000938902840807
  R&D Expenses-6.5%484518536544517
EBITDA30.2%565434385366-
EBITDA Margin24.9%0.19*0.16*0.14*0.14*-
Earnings Before Taxes48.0%391264230252257
EBT Margin42.1%0.13*0.09*0.05*0.07*-
Interest Expenses0%19.0019.0019.0019.0019.00
Net Income39.8%341244230258217
Net Income Margin34.2%0.12*0.09*0.06*0.09*-
Free Cahsflow16.6%30526121695.00-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets10.1%5,3924,8995,2175,0574,933
  Current Assets8.0%3,6693,3993,8093,7473,684
    Cash Equivalents-8.0%6426987357161,053
  Inventory-1.4%307311340342357
  Net PPE6.3%1,003943857802-
  Goodwill4.0%26.0025.0026.0027.0027.00
Liabilities6.0%3,2603,0752,9622,8682,891
  Current Liabilities104.3%1,839901807711721
Shareholder's Equity16.8%2,1321,8252,2562,1892,042
  Retained Earnings23.7%480388287236139
  Additional Paid-In Capital9.0%2,2582,0722,0291,9972,109
Shares Outstanding0.0%386386393392388
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations4.2%670643597486443
  Share Based Compensation6.5%127119116115113
Cashflow From Investing36.7%-521-823-1,023-515-216
Cashflow From Financing0.0%-552-55211.0015.0010.00
  Buy BacksInfinity%5580.000.00--

Risks for DXCM

What is the probability of a big loss on DXCM?

94.2%


Probability that DexCom stock will be more than 20% underwater in next one year

32.7%


Probability that DexCom stock will be more than 30% underwater in next one year.

29.6%


Probability that DexCom stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does DXCM drawdown profile look like?

Y-axis is the maximum loss one would have experienced if DexCom was unfortunately bought at previous high price.

Drawdowns

Returns for DXCM

Cumulative Returns on DXCM

39.5%


10-Year Cumulative Returns

33.5%


7-Year Cumulative Returns

47.3%


5-Year Cumulative Returns

23.1%


3-Year Cumulative Returns

What are the long-term rolling returns for DXCM?

FIve years rolling returns for DexCom.

Annualized Returns

Which funds bought or sold DXCM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
added
54.5
348,701
762,701
0.02%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-18.85
13,905,700
112,600,000
0.12%
2023-03-10
BAILLIE GIFFORD & CO
reduced
-4.43
501,188,000
1,959,380,000
2.04%
2023-03-08
Capital Asset Advisory Services LLC
new
-
206,210
206,210
0.02%
2023-03-06
Rockefeller Capital Management L.P.
added
1.45
4,034,000
13,495,000
0.07%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
225,121
225,121
-%
2023-02-28
Voya Investment Management LLC
reduced
-15.21
18,713,000
427,682,000
0.60%
2023-02-28
Orin Green Financial, LLC
unchanged
-
148,563
514,563
0.30%
2023-02-27
Parallax Volatility Advisers, L.P.
reduced
-99.77
-2,063,210
6,794
-%
2023-02-24
NATIXIS
added
0.97
1,930,330
6,743,330
0.04%

1–10 of 44

Latest Funds Activity

Are funds buying DXCM calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own DXCM
No. of Funds

DexCom News

Nasdaq

Validea's Top Ten Healthcare Stocks Based On John Neff - 3/19/2023.

Nasdaq,
11 hours ago

Seeking Alpha

Marketscreener.com

DexCom Comments on SVB Relationship.

Marketscreener.com,
6 days ago

Investor's Business Daily

The Motley Fool

Yahoo Finance

Investor's Business Daily

Yahoo Finance

Schedule 13G FIlings of DexCom

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 10, 2023
blackrock inc.
8.7%
33,535,680
SC 13G/A
Feb 09, 2023
vanguard group inc
11.34%
43,819,836
SC 13G/A
Jan 27, 2023
blackrock inc.
8.7%
33,882,680
SC 13G/A
Jan 25, 2023
blackrock inc.
8.8%
33,882,680
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 09, 2022
vanguard group inc
10.74%
10,410,319
SC 13G/A
Feb 08, 2022
blackrock inc.
8.4%
8,128,454
SC 13G/A
Dec 06, 2021
baillie gifford & co
4.85%
4,700,380
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
2.2%
2,139,304
SC 13G/A
Feb 10, 2021
vanguard group inc
10.66%
10,232,245
SC 13G/A

DXCM Fair Value

DexCom fair value in different scenarios

The table shows the Fair Value estimates for DexCom for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

28.52

-75.10%

36.46

-68.17%

66.99

-41.52%

109.59

-4.34%

133.44

16.48%
Current Inflation

26.07

-77.24%

32.84

-71.33%

58.89

-48.59%

94.82

-17.23%

114.78

0.19%
Very High Inflation

23.05

-79.88%

28.46

-75.16%

49.35

-56.92%

77.71

-32.17%

93.30

-18.56%

Historical DexCom Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of DexCom

View All Filings
Date Filed Form Type Document
Mar 15, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading
Mar 14, 2023
4
Insider Trading

Latest Insider Trading transactions for DXCM

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-14
Stern Sadie
sold
-43,961
111
-393
evp chief human resources offi
2023-03-13
Regan Barry J.
sold
-213,603
106
-2,010
evp operations
2023-03-13
Flynn Paul R
sold
-295,643
106
-2,782
evp global revenue
2023-03-13
Dolan Matthew Vincent
sold
-661,956
106
-6,229
svp corporate strategy-develop
2023-03-10
Stern Sadie
back to issuer
-681,205
111
-6,115
evp chief human resources offi
2023-03-10
Pacelli Steven Robert
back to issuer
-1,299,910
111
-11,669
evp managing director dexcom v
2023-03-10
Leach Jacob Steven
back to issuer
-1,794,530
111
-16,109
evp chief technology officer
2023-03-10
Abbey Donald
back to issuer
-1,299,910
111
-11,669
evp global business services i
2023-03-10
Regan Barry J.
back to issuer
-632,746
111
-5,680
evp operations
2023-03-10
Selvaraj Shelly Ramasamy
back to issuer
-720,974
111
-6,472
svp chief information officer

1–10 of 50

Kevin R. Sayer
6300
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DXCM Income Statement

2022-09-30
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
[1]
Sep. 30, 2022
Sep. 30, 2021
[1]
Income Statement [Abstract]    
Revenue$ 769.6$ 650.2$ 2,094.6$ 1,750.3
Cost of sales275.4203.3752.8542.4
Gross profit494.2446.91,341.81,207.9
Operating expenses:    
Research and development110.3128.8367.9367.3
Amortization of intangible assets1.81.35.72.3
Selling, general and administrative234.6198.5702.4573.1
Total operating expenses346.7328.61,076.0942.7
Operating income147.5118.3265.8265.2
Interest expense(4.6)(4.6)(13.9)(14.1)
Income from equity investments0.00.00.20.0
Interest and other income (expense), net3.3(1.7)5.5(0.7)
Income before income taxes146.2112.0257.6250.4
Income tax expense45.024.78.228.2
Net income$ 101.2$ 87.3[2]$ 249.4$ 222.2[3]
Basic net income per share (USD per share)$ 0.26$ 0.23$ 0.64$ 0.57
Shares used to compute basic net income per share (shares)389.8387.4390.4386.5
Diluted net income per share (USD per share)$ 0.24$ 0.21$ 0.60$ 0.54
Shares used to compute diluted net income per share (shares)425.8430.3428.0427.9
[1]* We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” for further information.
[2]* We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” for further information.
[3]* We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” for further information.

DXCM Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
[1]
Current assets:  
Cash and cash equivalents$ 698.1$ 1,052.6
Short-term marketable securities1,673.81,678.6
Accounts receivable, net564.1514.3
Inventory311.0357.3
Prepaid and other current assets151.581.6
Total current assets3,398.53,684.4
Property and equipment, net1,002.5801.8
Operating lease right-of-use assets73.188.1
Goodwill24.726.5
Intangibles, net24.431.5
Deferred tax assets342.3290.5
Other assets33.710.5
Total assets4,899.24,933.3
Current liabilities:  
Accounts payable and accrued liabilities764.2573.0
Accrued payroll and related expenses112.7125.2
Short-term operating lease liabilities20.920.5
Deferred revenue2.72.1
Total current liabilities900.5720.8
Long-term senior convertible notes1,968.81,981.8
Long-term operating lease liabilities82.198.6
Other long-term liabilities123.390.0
Total liabilities3,074.72,891.2
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at September 30, 2022 and December 31, 20210.00.0
Common stock, $0.001 par value, 800.0 million shares authorized; 393.1 million and 386.2 million shares issued and outstanding, respectively, at September 30, 2022; and 391.4 million and 388.0 million shares issued and outstanding, respectively, at December 31, 20210.40.4
Additional paid-in capital2,072.12,108.7
Accumulated other comprehensive income (loss)(41.1)0.5
Retained earnings388.1138.7
Treasury stock, at cost; 6.9 million shares at September 30, 2022 and 3.4 million shares at December 31, 2021(595.0)(206.2)
Total stockholders’ equity1,824.52,042.1
Total liabilities and stockholders’ equity$ 4,899.2$ 4,933.3
[1]* We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” for further information.